Granisetron Torrent Pharma (Uk)

Granisetron Torrent Pharma (UK) is a prescription medication whose active ingredient is granisetron. It is supplied in oral dosage form, with strength not specified in the available data, and is marketed in the European Union. Granisetron belongs to the 5‑HT3 receptor antagonist class and is used as an antiemetic to help prevent nausea and vomiting associated with chemotherapy or surgery or other medically induced triggers.

Granisetron Torrent Pharma is indicated for the prevention of nausea and vomiting in several clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - Use as part of antiemetic regimens for radiotherapy‑related nausea. - Adjunct therapy for patients receiving highly emetogenic treatments. - Management of nausea associated with diagnostic procedures that use contrast agents. - Supportive care for nausea in patients with gastrointestinal disorders when other treatments are insufficient.

The safety profile of granisetron includes both common and less frequent adverse effects.

Common: - Headache. - Constipation. - Diarrhea. - Fatigue. - Dizziness.

Serious: - Allergic reactions such as rash or itching. - Severe cardiac arrhythmias. - QT interval prolongation. - Anaphylaxis (rare). - Serotonin syndrome when combined with serotonergic agents.

Before initiating therapy with Granisetron Torrent Pharma, clinicians should consider several precautionary factors.

- Assess patient history for cardiac conduction abnormalities. - Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients receiving other drugs that affect QT interval. - Monitor renal or hepatic impairment, as dose adjustment may be required. - Consider pregnancy and breastfeeding status; safety data are limited. - Review concomitant use of serotonergic medications.

Granisetron may interact with other medications, influencing efficacy or safety.

Avoid: - Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics). - Concurrent use with other 5‑HT3 antagonists.

Use with caution: - Antidepressants that increase serotonin levels (SSRIs, SNRIs, MAO inhibitors). - Antifungal agents such as ketoconazole that affect metabolism. - Anesthetics or opioids that can also cause nausea.